Thor Medical ASA Asset Resilience Ratio
Thor Medical ASA asset resilience ratio. Thor Medical ASA (TRMED) has an Asset Resilience Ratio of 25.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TRMED cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Thor Medical ASA (2020–2024)
Asset resilience ratio of Thor Medical ASA from 2020 to 2024. This chart shows how Thor Medical ASA's Asset Resilience Ratio has changed over time. Read TRMED liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Thor Medical ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Thor Medical ASA balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr180.56 Million | 25.48% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr180.56 Million | 25.48% |
Asset Resilience Insights
- Very High Liquidity: Thor Medical ASA maintains exceptional liquid asset reserves at 25.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Thor Medical ASA Industry Peers by Asset Resilience Ratio
Compare Thor Medical ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Thor Medical ASA Asset Resilience Ratio by Year (2020–2024)
Thor Medical ASA asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Thor Medical ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | Nkr1.00K ≈ $105.23 |
Nkr414.40 Million ≈ $43.61 Million |
-12.77pp |
| 2023-12-31 | 12.77% | Nkr42.25 Million ≈ $4.45 Million |
Nkr330.83 Million ≈ $34.81 Million |
-77.26pp |
| 2022-12-31 | 90.03% | Nkr98.72 Million ≈ $10.39 Million |
Nkr109.64 Million ≈ $11.54 Million |
-3.57pp |
| 2021-12-31 | 93.61% | Nkr277.71 Million ≈ $29.22 Million |
Nkr296.67 Million ≈ $31.22 Million |
+0.17pp |
| 2020-12-31 | 93.44% | Nkr293.98 Million ≈ $30.93 Million |
Nkr314.61 Million ≈ $33.11 Million |
-- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.